Novel (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives of formula
the pharmaceutical acceptable acid addition salts thereof and the stereochemically isomeric forms thereof, wherein -X1 =X2- is -CH = CH-, -CH = N-, or -N = CH-; R is hydrogen or C1-6alkyl; Y is hydrogen, C1-10alkyl, C3-7cycloalkyl, Arl, Ar2-C1-6alkyl, C2-6alkenyl or C2-6alkynyl; Z is a radical of formula
which compounds are useful for treating disorders which are characterized by an excessive proliferation and/or abnormal differentiation of epithelial tissues: pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.
式中的新型(1H-唑-1-基
甲基)取代的
喹啉、
喹唑啉或
喹喔啉衍
生物
其中 -X1 =X2- 是 -CH = CH-、-CH = N-或 -N = CH-;R 是
氢或 C1-6 烷基;Y 是
氢、C1-10 烷基、C3-7
环烷基、Arl、Ar2-C1-6 烷基、C2-6
烯基或 C2-6 烷炔基;Z 是式中的一个基团
这些化合物可用于治疗以上皮组织过度增殖和/或异常分化为特征的疾病:含有此类化合物作为活性成分的药物组合物,以及制备所述化合物和药物组合物的方法。